Merrimack acquires European and Asian rights to nanoliposomal irinotecan
This article was originally published in Scrip
Executive Summary
Merrimack Pharmaceuticals has acquired from PharmaEngine the European and Asian rights to the cancer drug, MM-398 (a nanoliposomal formulation of irinotecan, also known as PEP02), in a deal re-structure that will see the latter receive $220 million in upfront and milestone payments in addition to royalties.